TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05443295

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MoveUS Program
Description: The MoveUS Program have 5 stages: 1 (approach stage), based on analytical movements, isometric peak contractions and learning/motor control; 2 (structural stage), based on muscular strength or resistance training through a cumulative work of short efforts, following with the analytical work of pushing or lifting/pulling; and ending in a closed kinetic chain; 3 (neural stage), that has two stage: 3A, based on a structural work that serves as a continuation of stage 2 and the work is focused on the training of increase cross-sectional muscular area; and 3B, based on a neural work focursed in an intra neuromuscular system highlighted motoneuron unit workout. Finally, stage 4 (functional stage), based on a functional readaptation to sports activity and/or work activity; or, failing that, to the activity of daily life with the highest demand.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control intervention
Description: The control intervention is based on following the conventional treatment guidelines for glenohumeral instability, where immobilization, taking non-steroidal anti-inflammatory drugs, cryotherapy, passive kinesitherapy and self-assisted, pendular exercises stand out and education.
Study: NCT06599229

Intervention type: DIAGNOSTIC_TEST
Intervention: myocardial contrast echo
Description: Vasodilator stress myocardial contrast echocardiography will be performed at baseline and within 4 months of reaching target dose of a cardiac myosin inhibitor.
Study: NCT06594965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20106
Description: HS-20106 administered subcutaneously every 4 weeks for up to 6 cycles. Eligible participants may be able to continue to receive subcutaneously administered HS-20106 after completing 6 cycles in the extended treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20106
Description: HS-20106 administered subcutaneously every 4 weeks for up to 6 cycles. Eligible participants may be able to continue to receive subcutaneously administered HS-20106 after completing 6 cycles in the extended treatment period.
Study: NCT06590844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injectable coenzyme I
Description: On the first day, we will treat patients with Tybo Sulsintilimab ® 200mg IV and Dalutin ® Bevacizumab 15mg/kg IV every 21 days. The first to third days were treated with injectable coenzyme I, 100mg/day IV, every 21 days as a cycle.
Study: NCT05234112

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: hrHPV self-testing
Description: use of swabs that women insert in the vagina for taking sufficient material for testing for hrHPV. For women who are not confident to perform this this nurses provide assistance.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: hrHPV self-testing
Description: use of swabs that women insert in the vagina for taking sufficient material for testing for hrHPV. For women who are not confident to perform this this nurses provide assistance.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Follow-up after testing
Description: based on the results of the test, follow-up is offered. In case of hrHPV negative test, retesting after five years. In case of hrHPV positive test, VIA in a nearby clinic. Women have to be motivated to adhere to follow-up

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Follow-up after testing
Description: based on the results of the test, follow-up is offered. In case of hrHPV negative test, retesting after five years. In case of hrHPV positive test, VIA in a nearby clinic. Women have to be motivated to adhere to follow-up

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: VIA
Description: Test offers insight into existence of dysplasia of the cervix by colouring the transition area
Study: NCT06589622

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Atraumatic Restorative Treatment
Description: Caries excavation with hand instruments only and restoration with Glass ionomer filling

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hall technique
Description: Crown placement without tooth preparation
Study: NCT06592235

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06594822

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotic plus standard treatment
Description: Bacillus clausii, 5ml ampule containing 2 billion spores, given orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: diclofenac 50 mg twice a day, prednisone 5mg once daily, methotrexate 10mg once weekly or sulfasalazine 500 twice daily
Study: NCT05234112

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thermo-ablation or cryotherapy for dysplasia
Description: Women with identified dysplasia lesions are offered immediate therapy to remove the infected superficial surface of the cervix

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thermo-ablation or cryotherapy for dysplasia
Description: Women with identified dysplasia lesions are offered immediate therapy to remove the infected superficial surface of the cervix

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pap smear cytology
Description: Cytology for identification of abnormal cells in the cervix, and classification of stages of dysplasia or pre-cancerous lesions
Study: NCT06253091

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robit-assist extraperitoneal laparoscopic radical cystectomy
Description: robit-assist laparoscopic radical cystectomy was performed extraperitoneal
Study: NCT04906408

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prevena
Description: Incisions will be dressed with closed incisional negative pressure wound therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prineo
Description: Incisions will be dressed with Prineo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Traditional
Description: Incisions will be dressed with bacitracin/xeroform
Study: NCT06425874

Intervention type: PROCEDURE
Intervention: Breast-conserving surgery
Description: Breast-conserving surgery

Intervention type: PROCEDURE
Intervention: Mastectomy
Description: Mastectomy without reconstruction

Intervention type: PROCEDURE
Intervention: Mastectomy with reconstruction
Description: Any type of reconstruction(include implant and autologous)
Study: NCT04708925

Intervention type: OTHER
Intervention: conservative versus plasmapharesis therapy
Description: conservative versus plasmapharesis therapy
Study: NCT06227078

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kinesiotaping
Description: Kinesiotaping is commonly used in sports medicine and rehabilitation settings. It is applied by trained professionals, such as physiotherapists or athletic trainers, who are skilled in assessing individual needs and determining the appropriate taping technique for specific conditions. The tape is typically worn for several days, allowing for continuous therapeutic effects.~It's important to note that while kinesiotaping has gained popularity, its effectiveness is still a subject of ongoing research, and its application should be part of a comprehensive treatment plan. Individual responses to kinesiotape may vary, and its use is often combined with other therapeutic interventions for optimal results.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Kinesiotaping
Description: Kinesiotaping is commonly used in sports medicine and rehabilitation settings. It is applied by trained professionals, such as physiotherapists or athletic trainers, who are skilled in assessing individual needs and determining the appropriate taping technique for specific conditions. The tape is typically worn for several days, allowing for continuous therapeutic effects.~It's important to note that while kinesiotaping has gained popularity, its effectiveness is still a subject of ongoing research, and its application should be part of a comprehensive treatment plan. Individual responses to kinesiotape may vary, and its use is often combined with other therapeutic interventions for optimal results.
Study: NCT05344040

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remotely Delivered and Supported Aerobic Walking Exercise Training
Description: This condition will include 16-weeks of remotely-delivered and supported aerobic walking exercise training based on guidelines for physical activity in persons with MS for general health benefits. Exercise intensities will be prescribed based on steps per exercise sessions from a waist-worn FitBit One™ (FitBit, Inc., San Francisco, CA).~The exercise program involves one-on-one semi-structured sessions with an MS exercise specialist (i.e., behavior coach) throughout the program. These sessions focus on exercise training guidance and oversight, discussion of the behavioral strategies of action planning and self-monitoring, and presentation and discussion of newsletters for optimizing exercise compliance.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Remotely Delivered and Supported Stretching and Toning Exercise Training
Description: The active, non-aerobic exercise condition will involve stretching-and-toning activities. These activities will be based on a manual provided by the National Multiple Sclerosis Society. Participants will be provided with necessary exercise equipment (e.g., yoga mat, FitBit), an instructional DVD, and a manual, log-book, calendar, and prescription for the stretching program. This program will be supplemented with periodic newsletters delivered electronically that highlight principles of behavior change, and video-chats with a behavior coach that provide motivation and social accountability. These occur on the same timeline and frequency as in the walking condition, but focus on constructs for stretching.
Study: NCT06590519

Intervention type: OTHER
Group type: OTHER
Intervention: Date Seed Extract
Description: Intervention group participants will undergo a three-month intervention program. The Health Belief Model (HBM) will be the underlying theory to facilitate behaviour change.~The intervention group will receive a capsule of date-seed-powder. Each person should consume 5 grams (two capsules of date-seed powder)twice daily after meals for three months.~Assessments are carried out at the beginning of the study, one month and two months after the intervention on the effect of date-seed on glycaemic control,risk of cardiovascular, physical activity, daytime sleepiness and anthropometric measurements. Participants will be contacted twice a week to ensure that they are adhering to the rules.
Study: NCT05790577

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin and Nicotinamide vs Kligman Formula
Description: Comparison of 30% Metformin and 2% Nicotinamide lotion with kligman formula in the treatment of Melasma

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin and Nicotinamide vs Kligman Formula
Description: Comparison of 30% Metformin and 2% Nicotinamide lotion with kligman formula in the treatment of Melasma
Study: NCT06058754

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The ADAPT Program
Description: The ADAPT Program is a structured and individualized 10-week group-based program, in which two occupational therapists teach groups of people, the skills of problem-solving more efficiently as means to overcome ADL task performance problems. The ADAPT Program 3.0 includes 2 individual two-hour sessions (sessions 1 and 10) conducted in the clients homes and eight two-hour group-based sessions (sessions 2-9). Moreover, two booster sessions (sessions 11 and 12) are delivered to support sustainable gains after termination of the 10-week ADAPT Program 3.0

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: UOT
Description: UOT is delivered by one occupational therapist. Sessions are individualised and focused on improving ADL ability e.g. by practicing the performance of ADL task or adjusting home environments. UOT typically includes 7 one-to-one sessions of 60 minutes, delivered over a 10-week period in the clients´ homes. The dose is however not fixed but based on the occupational therapists´ clinical judgement in collaboration with the individual client
Study: NCT06600113

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education and teaching of coping strategies
Description: the intervention consists of patient education for children, the same content delivered through either an educational game and storytelling

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education and teaching of coping strategies
Description: the intervention consists of patient education for children, the same content delivered through either an educational game and storytelling
Study: NCT06602375

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: The standard care (control) group will follow the plan of care determined by their treating dental provider. These decisions will be based on the clinical judgment of the dental provider and subject desires. Intervention may include, but is not limited to typical patient education, pharmacotherapy, oral splinting or occlusal device, cryo/thermotherapy recommendations, and exercise handouts.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: The standard care (control) group will follow the plan of care determined by their treating dental provider. These decisions will be based on the clinical judgment of the dental provider and subject desires. Intervention may include, but is not limited to typical patient education, pharmacotherapy, oral splinting or occlusal device, cryo/thermotherapy recommendations, and exercise handouts.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy (PT)
Description: Participants randomized to this group will receive individualized, tailored courses of physical therapy care. Interventions may be directed at the temporomandibular, cervical, and/or scapulothoracic regions based on subject clinical presentation and impairments. Manual therapy joint and soft tissue mobilizations may be used to address pain, mobility, and motor control. Motor control exercises may be used to promote relaxation, improve range of motion, and appropriate postures. Strengthening exercise, primarily directed to the cervical and scapulothoracic regions, may be implemented as appropriate. Stretching exercise may be used to address pain and mobility deficits. The interventions are intentionally pragmatic; study participants will receive treatment as they are comfortable and as recommended by the treating therapist.
Study: NCT06589947

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensified BP control
Description: Treatment goal in the intensified group will be lowering BP ≤60th pct.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: Standard treatment is to achieve BP levels \&lt;90th pct.
Study: NCT06600880

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuronavigation-guided single-element focused ultrasound transducer
Description: Non-invasive focused ultrasound-induced blood-brain barrier opening will be attempted using a single-element transducer, guided with a neuronavigation system.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumason
Description: New packages of Lumason microbubbles will be shipped from Bracco Diagnostics Inc. and will be used in conjunction with the ultrasound transducer to temporarily open the BBB. Lumason microbubbles will be freshly activated before treatment sonication and will be drawn using a 10-ml syringe to reach the desired dosage of 0.1mL/kg right before the intravenous injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents
Description: A high-resolution MRI (with and without gadolinium (Dotarem) contrast agent) will be acquired prior to BBB opening on the GE SIGNATM Premier (3T) (same scanner as in the NHP study) for pre-treatment planning and screening purposes. Then, a second MRI (with and without gadolinium) will be acquired and read by a Board-Certified Radiologist immediately after the treatment sonication in order to assess the BBB opening and safety. Finally, a final follow-up MRI (with and without gadolinium) will be conducted 3 days (±1 day) after the treatment to confirm BBB closing and/or safety. This will be read by a Board-Certified Radiologist as well.~All MRI procedures will be performed at the CUIMC/Neurological Institute of New York.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)
Description: A first PET/CT scan with Amyvid (18F-Florbetapir) and MK-6240 (F18-Florquinitau) tracers will be performed on the SIEMENS Biograph 64 to assess the baseline amyloid plaque load and tau load before the treatment, respectively. Finally, two follow-up PET/CT scans will be conducted 3 weeks (±1 week) and 3 months (±2 weeks) post-treatment to assess amyloid plaque load (using Amyvid) and tau load (using MK-6240).
Study: NCT06448832

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: An ultrasound examination of the musculature of the plantar muscle and long palmar muscle is performed to determine their presence or absence.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: An ultrasound examination of the musculature of the plantar muscle and long palmar muscle is performed to determine their presence or absence.
Study: NCT06140706

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: transcutaneous Spinal Cord Stimulation (tSCS)
Description: Neurostimulation for upper extremity training, delivered through video telehealth, 8 weeks of home use for (i) feasibility and (ii) potential functional improvement.
Study: NCT06212401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patients received dexmedetomidine as a bolus over 10 minutes in a dose of 1ug/kg followed by an infusion at the rate of 0.5ug/kg/hr

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketofole
Description: Patients received ketofol 1mg/kg over 10 minutes followed by 50ug/kg/min of infusion
Study: NCT05172427

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 14 days of EMI
Description: Following the intervention, participants will receive personalized prompts whenever they report elevated stress or anxiety. These prompts will be generated at the end of the intervention session, and will only be sent to individuals in the EMI condition.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Uncertainty reappraisal training
Description: CLUE consists of an hour long intervention, followed by a 2-week long EMI. During the hour long intervention session, participants will receive psychoeducation (i.e., defining uncertainty), discuss myths associated with uncertainty (e.g., if I do not plan things, they will go poorly), and discuss behavioral experiments that can be done to challenge uncertainty beliefs.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Uncertainty reappraisal training
Description: CLUE consists of an hour long intervention, followed by a 2-week long EMI. During the hour long intervention session, participants will receive psychoeducation (i.e., defining uncertainty), discuss myths associated with uncertainty (e.g., if I do not plan things, they will go poorly), and discuss behavioral experiments that can be done to challenge uncertainty beliefs.
Study: NCT05984004

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl isotonic saline solution
Description: The placebo-control in the phase I study was a 0.9% NaCl isotonic saline solution. This nasal spray solution has no pharmacological effect, but is considered to have a cleansing effect on the nose, supporting the treatment of nasal symptoms in nasal pathology. The solution is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19). The solution is bottled in the same fully-sealed nasal spray device containing Bacillus subtilis DSM 32444 postbiotic, used for Sperovid.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Bacillus subtilis DSM32444, inactivated
Description: Postbiotic DSM32444 is manufactured by HURO BIOTECH Company as a drug-grade active pharmaceutical ingredient. The Class A medical device containing Postbiotic DSM32444 is called Sperovid, which is manufactured by Dong Duoc Viet under ISO 13485:2016 standards for medical device. Sperovid has registration number: 220000033/PCBA-LA
Study: NCT06183749

Intervention type: OTHER
Intervention: hospitalisation for more than 24 hours in the 3rd stage Anesthesiology and Reanimation unit
Description: diagnosed as traumatic brain injury by neurosurgery in the emergency department and hospitalized for more than 24 hours in the 3rd stage Anesthesiology and Reanimation unit and receivied appropriate necessary treatment

Intervention type: OTHER
Intervention: hospitalisation for more than 24 hours in the 3rd stage Anesthesiology and Reanimation unit
Description: diagnosed as traumatic brain injury by neurosurgery in the emergency department and hospitalized for more than 24 hours in the 3rd stage Anesthesiology and Reanimation unit and receivied appropriate necessary treatment